anti-GARP monoclonal antibody JYB 1907
Term · Oncology and biomedicine · MLC-T-ONC-010681
A humanized monoclonal antibody directed against the transforming growth factor beta (TGFbeta) activator glycoprotein A repetitions predominant (GARP; leucine-rich repeat-containing protein 32; LRRC32), with potential immunomodulating and antineoplastic activities. Upon administration, anti-GARP monoclonal antibody JYB1907 selectively targets and binds to GARP. This specifically blocks the GARP-mediated release of the cytokine transforming growth factor-beta 1 (TGF-b1), thereby relieving the immunosuppression caused by TGF-b1 and reversing the immunosuppressive nature in the tumor microenvironment (TME). This improves anti-tumor immune responses GARP, a transmembrane protein highly expressed on activated, immunosuppressive regulatory T cells (Tregs) in the TME, is essential for the expression of TGF-b1 on the cell surface of activated Tregs; it plays an important role in regulation of the immune cell function and the immunosuppressive nature of Tregs. TGF-b1 stimulates stromal cell proliferation, neovascularization, cancer cell metastasis, and inhibits immune cell infiltration.
| Identifier | MLC-T-ONC-010681 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-glycoprotein A repetitions predominant monoclonal antibody JYB1907 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010681",
"term": "anti-GARP monoclonal antibody JYB 1907",
"field": "Oncology and biomedicine",
"definition": "A humanized monoclonal antibody directed against the transforming growth factor beta (TGFbeta) activator glycoprotein A repetitions predominant (GARP; leucine-rich repeat-containing protein 32; LRRC32), with potential immunomodulating and antineoplastic activities. Upon administration, anti-GARP monoclonal antibody JYB1907 selectively targets and binds to GARP. This specifically blocks the GARP-mediated release of the cytokine transforming growth factor-beta 1 (TGF-b1), thereby relieving the immunosuppression caused by TGF-b1 and reversing the immunosuppressive nature in the tumor microenvironment (TME). This improves anti-tumor immune responses GARP, a transmembrane protein highly expressed on activated, immunosuppressive regulatory T cells (Tregs) in the TME, is essential for the expression of TGF-b1 on the cell surface of activated Tregs; it plays an important role in regulation of the immune cell function and the immunosuppressive nature of Tregs. TGF-b1 stimulates stromal cell proliferation, neovascularization, cancer cell metastasis, and inhibits immune cell infiltration.",
"synonyms": [
"anti-glycoprotein A repetitions predominant monoclonal antibody JYB1907"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-garp-monoclonal-antibody-jyb-1907/"
}
Record 1,784 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.